TARSONS319.00

Tarsons Products Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersFISCHERLAXMIDENTLFABTECHGKBMcap ₹1,697 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q4 FY22
31/03/2022
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations84.961.8105.784.899.295.7112.791.4102.3107.9120.9110.2
Other Income2.63.23.42.98.40.83.83.35.88.46.66.0
Total Income87.565.0109.187.7107.796.5116.594.7108.1116.3127.5116.2
Expenses
+ Cost of Materials Consumed20.015.316.320.318.319.621.915.817.317.921.922.2
+ Purchases of Stock-in-Trade2.92.08.715.113.011.211.810.610.414.314.512.6
+ Changes in Inventories-3.9-0.78.2-7.71.40.54.22.95.53.04.83.9
+ Employee Benefit Expense8.69.815.616.116.116.416.817.917.819.520.421.2
+ Finance Costs0.52.54.34.34.85.05.25.15.26.06.36.3
+ Depreciation & Amortisation7.210.112.311.014.017.420.019.922.525.029.127.0
+ Other Expenses13.012.526.722.325.218.421.019.523.821.725.124.3
Total Expenses48.351.592.181.492.888.5100.991.7102.5107.5122.0117.5
EBITDA44.322.930.218.825.329.637.024.727.431.534.326.0
EBIT37.112.817.97.711.312.217.04.85.06.55.2-1.0
Profit
PBT before Exceptional Items39.213.617.06.314.98.015.63.05.68.95.5-1.3
+ Exceptional Items0.00.00.00.00.00.00.00.00.0-1.30.20.0
Pretax Income39.213.617.06.314.98.015.63.05.67.55.8-1.3
+ Current Tax9.13.38.22.53.62.56.31.32.32.50.00.2
+ Deferred Tax0.60.4-1.4-0.21.00.3-0.9-0.1-0.0-0.01.6-0.1
Tax Expense9.83.66.72.34.62.85.41.22.32.51.60.1
Net Income29.59.910.34.010.35.310.21.83.35.04.2-1.4
+ Net Income — Continuing Ops29.59.910.34.010.35.310.21.83.35.04.2-1.4
+ Other Comprehensive Income0.3-0.01.50.4-3.03.5-2.7-5.9-2.8-0.5-0.70.6
Total Comprehensive Income29.79.911.84.47.38.87.5-4.10.54.63.5-0.9
Per Share
Basic EPS5.691.871.940.751.930.991.920.340.620.950.79-0.27
Diluted EPS5.691.871.940.751.930.991.920.340.620.950.79-0.27
Other Comprehensive Income — detail
+ Other Comprehensive Income-2.7-5.9-2.8-0.5-0.70.6
+ Items NOT to be Reclassified to P&L-0.0-0.0-0.0-0.0-0.1-0.1-0.40.2
+ Tax on Items NOT to be Reclassified-0.0-0.00.30.0
+ Tax on Items NOT to be Reclassified — alt tag-0.0-0.0-0.0-0.0
+ Items to be Reclassified to P&L1.60.4-3.03.5-2.7-5.9-2.8-0.40.4
+ Tax on Items to be Reclassified-0.0-0.00.00.00.00.0
+ Tax on Items to be Reclassified — alt tag0.10.00.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations5.691.871.940.751.930.991.920.340.620.950.79-0.27
Diluted EPS — Continuing Operations5.691.871.940.751.930.991.920.340.620.950.79-0.27
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit66.045.172.557.166.664.474.862.169.172.779.771.5
Gross Margin %77.6573.0468.5867.3667.1367.3466.3767.9367.5267.4365.9564.89
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)39.213.617.06.314.98.015.63.05.68.95.5-1.3
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.00.00.0-1.30.20.0
Net Income Adj (tax-effected)29.59.910.34.010.35.310.21.83.35.94.0-1.4
EPS Adj5.691.871.940.751.930.991.920.340.621.120.76-0.27
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital10.610.610.610.610.610.610.610.610.610.610.610.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.